Literature DB >> 7682874

Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis.

E Solcia1, G Rindi, E Silini, L Villani.   

Abstract

ECL cells are argyrophilic endocrine cells of the stomach. Their distribution is species specific, however they are consistently located in the oxyntic mucosa and, in particular, in very close contact with the adenomeres of acidopeptic glands. ECL cells store histamine and are considered a key element in the mechanisms of gastric acid secretion as controlled by gastrin stimulus. Their peculiar anatomical disposition and secretory properties strongly suggest that ECL cells exert their function by a paracrine mechanism, i.e. by releasing histamine in the extracellular spaces surrounding acid-producing parietal cells. ECL cell activity is strongly stimulated by gastrin, which, once applied as a long-standing stimulus, also exerts a potent proliferating effect. Long-lasting hypergastrinaemia has been demonstrated to elicit ECL cell proliferation in laboratory animals, inducing ECL cell hyperplasia, dysplasia and ECL cell tumours, i.e. argyrophilic gastric carcinoids. However, in experimental rodents it is believed that hypergastrinaemia is not per se a stimulus capable of inducing ECL cell transformation, a predisposing genetic background being required for tumour development in endocrine organs. In man, long-standing hypergastrinaemia exerts the same proliferative pressure on ECL cells and is associated with hyperplasia with or without dysplastic changes and carcinoid development. Clinical evidence suggests that other factors, both genetic and environmental, are required to induce ECL cell transformation and carcinoid development. For this reason human gastric argyrophilic ECL carcinoids are subdivided into three main groups depending on their clinical background: (1) gastric carcinoids in patients with chronic atrophic gastritis; (2) gastric carcinoids in patients with Zollinger-Ellison and multiple endocrine neoplasia type 1 syndrome (MEN-ZES); and (3) solitary, sporadic gastric carcinoids. The clinical assessment of carcinoid-bearing patients is strongly recommended for better diagnosis and management of patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682874     DOI: 10.1016/0950-3528(93)90035-q

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  19 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Gastric neuroendocrine carcinoma associated with chronic atrophic gastritis type A.

Authors:  Y Kaizaki; T Fujii; T Kawai; K Saito; K Kurihara; M Fukayama
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

Review 3.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

4.  Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.

Authors:  D K Driman; C Wright; G Tougas; R H Riddell
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

5.  Observations on relationship between hypergastrinemia, multiple gastric carcinoids, and pancreatic mass.

Authors:  I M Modlin; C J Gilligan; G P Lawton; L H Tang; A B West; R Lindenberg
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

Review 6.  Somatostatin analogs for gastric carcinoids: For many, but not all.

Authors:  Sara Massironi; Alessandra Zilli; Dario Conte
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

7.  Gastric carcinoid in a patient infected with Helicobacter pylori: a new entity?

Authors:  Pantelis Antonodimitrakis; Apostolos Tsolakis; Staffan Welin; Gordana Kozlovacki; Kjell Oberg; Dan Granberg
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

Review 8.  Autoimmune atrophic gastritis--pathogenesis, pathology and management.

Authors:  William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-18       Impact factor: 46.802

9.  Treatment of gastric carcinoids.

Authors:  Wei Hou; Mitchell L Schubert
Journal:  Curr Treat Options Gastroenterol       Date:  2007-04

Review 10.  Multiple carcinoids in the duodenum, pancreas and stomach accompanied with type A gastritis: a case report.

Authors:  Takeo Bamba; Shinichi Kosugi; Tatsuo Kanda; Toshihiro Tsubono; Yasuo Sakai; Nobuyuki Musha; Noriko Ishihara; Katsuyoshi Hatakeyama
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.